2160.T
GNI Group Ltd.
グロース · 医薬品 · 医薬品 · JP
JPY 2,805.00
+0.94%Year over year
Reported trailing growth
- Revenue
- +13.7%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +25.6%
- Operating cash flow
- +23.9%
Forward estimates
Based on analyst estimates
- Revenue
- +7.1%
- EBITDA
- —
- EPS
- +395.0%
Three-year CAGR
- Revenue
- +15.5%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +25.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026